Publication Information

{'id': 'https://openalex.org/W2682941430', 'doi': 'https://doi.org/10.4155/fmc-2017-0099', 'title': 'Medicinal chemistry advances in neurodegenerative disease therapy: part 2', 'display_name': 'Medicinal chemistry advances in neurodegenerative disease therapy: part 2', 'publication_year': 2017, 'publication_date': '2017-06-01', 'ids': {'openalex': 'https://openalex.org/W2682941430', 'doi': 'https://doi.org/10.4155/fmc-2017-0099', 'mag': '2682941430', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/28632420'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.4155/fmc-2017-0099', 'pdf_url': 'https://www.future-science.com/doi/pdf/10.4155/fmc-2017-0099', 'source': {'id': 'https://openalex.org/S122867665', 'display_name': 'Future Medicinal Chemistry', 'issn_l': '1756-8919', 'issn': ['1756-8919', '1756-8927'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://www.future-science.com/doi/pdf/10.4155/fmc-2017-0099', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5081781935', 'display_name': 'Rachel Coleby', 'orcid': 'https://orcid.org/0000-0002-2490-0199'}, 'institutions': [{'id': 'https://openalex.org/I4210122326', 'display_name': 'Future Science Group (United Kingdom)', 'ror': 'https://ror.org/030shh572', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I4210122326']}], 'countries': ['GB'], 'is_corresponding': True, 'raw_author_name': 'Rachel Coleby', 'raw_affiliation_strings': ['Future Science Group – Unitec House, 2 Albert Place, LondonN3 1QB, UK'], 'affiliations': [{'raw_affiliation_string': 'Future Science Group – Unitec House, 2 Albert Place, LondonN3 1QB, UK', 'institution_ids': ['https://openalex.org/I4210122326']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5081781935'], 'corresponding_institution_ids': ['https://openalex.org/I4210122326'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.385, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.439029, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 71, 'max': 75}, 'biblio': {'volume': '9', 'issue': '10', 'first_page': '951', 'last_page': '952'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T12023', 'display_name': 'Cholinesterase and Neurodegenerative Diseases', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T12023', 'display_name': 'Cholinesterase and Neurodegenerative Diseases', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12915', 'display_name': 'Biochemical Acid Research Studies', 'score': 0.993, 'subfield': {'id': 'https://openalex.org/subfields/1303', 'display_name': 'Biochemistry'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10211', 'display_name': 'Computational Drug Discovery Methods', 'score': 0.989, 'subfield': {'id': 'https://openalex.org/subfields/1703', 'display_name': 'Computational Theory and Mathematics'}, 'field': {'id': 'https://openalex.org/fields/17', 'display_name': 'Computer Science'}, 'domain': {'id': 'https://openalex.org/domains/3', 'display_name': 'Physical Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.4787623}, {'id': 'https://openalex.org/C2779134260', 'wikidata': 'https://www.wikidata.org/wiki/Q12136', 'display_name': 'Disease', 'level': 2, 'score': 0.4734302}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.42841858}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.39221838}, {'id': 'https://openalex.org/C556039675', 'wikidata': 'https://www.wikidata.org/wiki/Q771035', 'display_name': 'Traditional medicine', 'level': 1, 'score': 0.33100677}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.14084473}], 'mesh': [{'descriptor_ui': 'D019636', 'descriptor_name': 'Neurodegenerative Diseases', 'qualifier_ui': 'Q000628', 'qualifier_name': 'therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000110', 'descriptor_name': 'Acetylcholinesterase', 'qualifier_ui': 'Q000737', 'qualifier_name': 'chemistry', 'is_major_topic': False}, {'descriptor_ui': 'D000110', 'descriptor_name': 'Acetylcholinesterase', 'qualifier_ui': 'Q000378', 'qualifier_name': 'metabolism', 'is_major_topic': False}, {'descriptor_ui': 'D000110', 'descriptor_name': 'Acetylcholinesterase', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D053829', 'descriptor_name': 'Amyloid Precursor Protein Secretases', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': False}, {'descriptor_ui': 'D053829', 'descriptor_name': 'Amyloid Precursor Protein Secretases', 'qualifier_ui': 'Q000378', 'qualifier_name': 'metabolism', 'is_major_topic': False}, {'descriptor_ui': 'D053829', 'descriptor_name': 'Amyloid Precursor Protein Secretases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000975', 'descriptor_name': 'Antioxidants', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000975', 'descriptor_name': 'Antioxidants', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D000975', 'descriptor_name': 'Antioxidants', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002800', 'descriptor_name': 'Cholinesterase Inhibitors', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D002800', 'descriptor_name': 'Cholinesterase Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D002800', 'descriptor_name': 'Cholinesterase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019636', 'descriptor_name': 'Neurodegenerative Diseases', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D019636', 'descriptor_name': 'Neurodegenerative Diseases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D066329', 'descriptor_name': 'Protein Aggregates', 'qualifier_ui': 'Q000187', 'qualifier_name': 'drug effects', 'is_major_topic': False}, {'descriptor_ui': 'D066329', 'descriptor_name': 'Protein Aggregates', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D051844', 'descriptor_name': 'alpha-Synuclein', 'qualifier_ui': 'Q000378', 'qualifier_name': 'metabolism', 'is_major_topic': False}, {'descriptor_ui': 'D051844', 'descriptor_name': 'alpha-Synuclein', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.4155/fmc-2017-0099', 'pdf_url': 'https://www.future-science.com/doi/pdf/10.4155/fmc-2017-0099', 'source': {'id': 'https://openalex.org/S122867665', 'display_name': 'Future Medicinal Chemistry', 'issn_l': '1756-8919', 'issn': ['1756-8919', '1756-8927'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28632420', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.4155/fmc-2017-0099', 'pdf_url': 'https://www.future-science.com/doi/pdf/10.4155/fmc-2017-0099', 'source': {'id': 'https://openalex.org/S122867665', 'display_name': 'Future Medicinal Chemistry', 'issn_l': '1756-8919', 'issn': ['1756-8919', '1756-8927'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 7, 'referenced_works': ['https://openalex.org/W2614737249', 'https://openalex.org/W2627864519', 'https://openalex.org/W2633685052', 'https://openalex.org/W2649839380', 'https://openalex.org/W2669329226', 'https://openalex.org/W2669747291', 'https://openalex.org/W2707932262'], 'related_works': ['https://openalex.org/W4387497383', 'https://openalex.org/W3031052312', 'https://openalex.org/W2948807893', 'https://openalex.org/W2899084033', 'https://openalex.org/W2778153218', 'https://openalex.org/W2748952813', 'https://openalex.org/W2607424097', 'https://openalex.org/W2606230654', 'https://openalex.org/W2319480705', 'https://openalex.org/W1531601525'], 'abstract_inverted_index': {'Future': [0, 35, 640, 703, 741, 770, 794, 821, 857, 882, 948, 979], 'Medicinal': [1, 186, 594], 'ChemistryVol.': [2], '9,': [3, 923], 'No.': [4, 906, 924], '10': [5, 925], 'Special': [6], 'Focus': [7], 'Issue': [8], '-': [9, 17], 'Advances': [10], 'in': [11, 22, 97, 105, 171, 204, 232, 330, 337, 356, 376, 418, 495, 501, 540, 551, 581, 589, 662, 673, 684, 731, 792, 816, 845, 943, 1001, 1012, 1023], 'neurodegenerative': [12, 23, 98, 146, 205, 612], 'disease': [13, 24, 99, 206, 282, 332, 411, 442, 556, 613, 818], 'therapy:': [14, 25], 'Part': [15], '2': [16, 41], 'ForewordFree': [18], 'AccessMedicinal': [19], 'chemistry': [20, 95, 203], 'advances': [21, 96], 'part': [26], '2Rachel': [27], 'ColebyRachel': [28], 'Coleby*Author': [29], 'for': [30, 70, 161, 280, 440, 465, 621, 626, 876, 911, 931, 960, 965], 'correspondence:': [31], 'E-mail': [32], 'Address:': [33], '[email protected]': [34], 'Science': [36, 641, 949, 980], 'Group': [37], '–': [38], 'Unitec': [39], 'House,': [40], 'Albert': [42], 'Place,': [43], 'London': [44], 'N3': [45], '1QB,': [46], 'UKPublished': [47], 'Online:20': [48], 'Jun': [49, 836], '2017https://doi.org/10.4155/fmc-2017-0099AboutSectionsPDF/EPUB': [50], 'ToolsAdd': [51], 'to': [52, 82, 93, 124, 174, 238, 350, 370, 481, 497, 508, 608, 618, 700, 789, 849, 957], 'favoritesDownload': [53], 'CitationsTrack': [54], 'CitationsPermissionsReprints': [55], 'ShareShare': [56], 'onFacebookTwitterLinkedInReddit': [57], 'Keywords:': [58], 'α-synucleinantiaggregating': [59], 'agentsmultitarget': [60, 951], 'compoundsneurodegenerationneuroregenerationprolyl': [61, 952], 'oligopeptidase': [62, 490, 514, 841, 953], 'inhibitorsFirst': [63], 'draft': [64], 'submitted:': [65], '13': [66], 'April': [67, 73, 106], '2017;': [68, 74], 'Accepted': [69], 'publication:': [71], '18': [72], 'Published': [75, 937, 942], 'online:': [76], '20': [77, 939], 'June': [78, 920, 940, 945], '2017We': [79], 'are': [80, 148], 'delighted': [81], 'introduce': [83], 'the': [84, 131, 141, 172, 176, 216, 246, 259, 273, 343, 377, 384, 415, 429, 451, 518, 545, 548, 552, 566, 586, 600, 609, 667, 674, 685, 697, 701, 846, 850, 877, 912, 932, 1006, 1013, 1024], 'second': [85, 177, 285, 764], 'installment': [86], 'of': [87, 133, 137, 179, 184, 193, 201, 221, 242, 249, 269, 276, 345, 374, 414, 432, 528, 547, 554, 568, 574, 592, 611, 639, 687, 762, 766, 879, 914, 978, 1026], 'this': [88, 120, 156, 338, 399, 419, 482, 541, 590, 688, 1027], 'special': [89, 181, 339, 400, 483, 629, 968], 'focus': [90, 182, 340, 401, 734], 'issue': [91, 183, 189, 341, 402, 484, 591], 'dedicated': [92], 'medicinal': [94, 202, 606], 'therapy': [100], '[1].The': [101], 'WHO': [102], 'estimated': [103], 'that': [104, 224, 383, 449, 585], '2016': [107], 'there': [108, 510], 'were': [109], '47.5': [110], 'million': [111, 128], 'people': [112], 'suffering': [113], 'from': [114, 288, 421, 560, 677, 1016], 'dementia': [115], 'worldwide,': [116], 'and': [117, 158, 195, 218, 229, 245, 258, 311, 314, 391, 409, 426, 492, 503, 526, 534, 577, 738, 758, 842, 853], 'by': [118, 155, 605], '2050': [119], 'number': [121, 136], 'could': [122, 326], 'triple': [123], 'a': [125, 134, 191, 236, 346, 354, 438, 659, 763, 786, 813, 891, 998], 'predicted': [126], '135.5': [127], '[2].': [129], 'Despite': [130], 'efforts': [132], 'huge': [135], 'research': [138, 197, 286, 335], 'groups': [139], 'around': [140], 'globe,': [142], 'at': [143, 471], 'present,': [144], 'all': [145], 'diseases': [147, 505], 'incurable': [149], 'with': [150, 168, 265, 272, 653, 658, 666, 992, 997, 1005], 'only': [151], 'palliative': [152], 'treatments': [153], 'available.Driven': [154], 'large': [157], 'increasing': [159], 'need': [160], 'new': [162, 347], 'therapies,': [163], 'we': [164], 'have': [165, 214, 300, 476, 523, 530], 'come': [166], 'together': [167], 'renowned': [169], 'experts': [170], 'field': [173], 'deliver': [175], 'half': [178], 'our': [180, 208, 284, 422, 627, 966], "'Future": [185, 593], "Chemistry'.": [187], 'The': [188, 317, 446, 558, 643, 982], 'features': [190], 'range': [192], 'reviews': [194, 404], 'original': [196, 397], 'covering': [198], 'various': [199], 'aspects': [200], 'therapy.In': [207], 'first': [209, 413], 'article,': [210], 'Simoni': [211, 719], 'et': [212, 360, 474, 562, 725, 754, 783], 'al.': [213, 361, 475, 563, 726, 755, 784], 'investigated': [215], 'design': [217, 729], 'biological': [219, 499, 760], 'evaluation': [220], 'hybrid': [222], 'compounds': [223, 264, 279, 299], 'target': [225, 321], 'both': [226, 268], 'cholinergic': [227, 243, 736], 'transmission': [228, 737], 'amyloid-β': [230], 'aggregation': [231, 576, 871], "Alzheimer's": [233, 281, 331, 357, 408, 441, 502, 732, 817], 'disease,': [234], 'as': [235, 307, 309, 353, 395, 437, 571, 623, 962], 'method': [237], 'provide': [239, 596], 'symptomatic': [240], 'relief': [241], 'potentiation': [244], 'neuroprotective': [247], 'prospects': [248], 'antiaggregating': [250], 'agents': [251], '[3].': [252], 'This': [253], 'is': [254, 511, 636, 975], 'an': [255, 364, 478, 637, 873, 976], 'interesting': [256, 430, 535], 'approach': [257, 875], 'authors': [260, 447], 'present': [261], 'some': [262, 527], 'promising': [263, 532, 852], 'activity': [266], 'against': [267], 'these': [270], 'features.Continuing': [271], 'same': [274], 'aim': [275], 'investigating': [277], 'multitarget': [278, 759], 'treatment,': [283], 'article': [287, 336, 539], "Munoz-Torrero's": [289], 'group': [290], 'focuses': [291, 543], 'on': [292, 406, 486, 517, 544, 696, 735, 901, 928], 'brain-permeable': [293], 'rhein–huprine': [294, 768], 'hybrids': [295], '[4].': [296], 'These': [297], 'second-generation': [298], 'potent': [301], 'acetylcholinesterase': [302, 375, 791], 'or': [303, 459, 650, 656, 663, 670, 989, 995, 1002, 1009], 'BACE-1': [304], 'inhibitory': [305], 'activities,': [306], 'well': [308, 394], 'Aβ42': [310], 'tau': [312], 'anti-aggregating': [313], 'antioxidant': [315], 'activities.': [316], 'identified': [318], 'compounds,': [319], 'which': [320], 'several': [322, 520], 'crucial': [323], 'pathogenic': [324], 'factors,': [325], 'be': [327, 351, 368, 462], 'extremely': [328], 'useful': [329, 597], 'treatment.Our': [333], 'final': [334, 538], 'reports': [342], 'development': [344, 567], 'potential': [348, 407, 579], 'radiotracer': [349, 788], 'used': [352, 369], 'probe': [355, 385], 'disease.': [358, 881], 'Fernández': [359, 777], 'investigate': [362], 'how': [363], 'indazole-based': [365], '[18F]-PET-probe': [366], 'can': [367], 'detect': [371], 'changing': [372], 'levels': [373], 'brain': [378, 453], '[5].': [379], 'Animal': [380], 'models': [381], 'demonstrated': [382], 'had': [386], 'good': [387], 'blood–brain': [388], 'barrier': [389], 'penetration': [390], 'reasonable': [392], 'half-lives.As': [393], 'featuring': [396], 'research,': [398], 'contains': [403], 'focusing': [405], "Parkinson's": [410, 504, 555, 582, 880], 'therapies.The': [412], 'review': [416, 480, 559, 894], 'articles': [417, 587], 'issue,': [420], 'guest': [423, 624, 963], 'editor': [424, 625, 964], 'Bolognesi': [425, 620, 690, 807, 959], 'co-workers': [427], 'investigates': [428], 'possibility': [431], 'targeting': [433, 450], 'neuroregeneration': [434], 'over': [435], 'neurodegeneration': [436], 'strategy': [439, 730], 'drug': [443, 614, 693, 728, 819], 'discovery': [444], '[6].': [445], 'highlight': [448], 'endogenous': [452], 'regenerative': [454], 'process': [455], 'using': [456], 'small': [457, 569], 'molecules': [458, 570], 'nanoparticles': [460], 'may': [461], 'more': [463], 'beneficial': [464], 'patient': [466], 'outcomes': [467], 'than': [468], 'therapies': [469], 'aimed': [470], 'reverting': [472], 'neurodegeneration.Babkova': [473], 'contributed': [477], 'insightful': [479], 'based': [485], 'naturally': [487], 'occurring': [488], 'prolyl': [489, 513], 'inhibitors': [491, 494], 'peptide-like': [493], 'relation': [496], 'their': [498, 578], 'effects': [500], '[7].': [506], 'Although': [507], 'date,': [509], 'no': [512, 646, 985], 'inhibitor': [515], 'available': [516], 'market,': [519], 'clinical': [521], 'trials': [522], 'been': [524], 'undertaken': [525], 'them': [529], 'shown': [531], 'results': [533], 'pharmacological': [536], 'profiles.Our': [537], 'series': [542], 'role': [546, 844], 'α-synuclein': [549, 575], 'protein': [550], 'pathogenesis': [553], '[8].': [557], 'Singh': [561, 864], 'also': [564], 'covers': [565], 'possible': [572], 'modulators': [573], 'application': [580], 'disease.We': [583], 'hope': [584], 'featured': [588], "Chemistry'": [595], 'insights': [598], 'into': [599], 'valuable': [601], 'contributions': [602], 'being': [603], 'made': [604], 'chemists': [607], 'advancement': [610], 'discovery.AcknowledgementsSpecial': [615], 'thanks': [616, 955], 'go': [617, 956], 'ML': [619, 958], 'serving': [622, 961], 'two-part': [628, 967], 'issue.Financial': [630, 969], '&': [631, 970], 'competing': [632, 971], 'interests': [633, 972], 'disclosureR': [634, 973], 'Coleby': [635, 974], 'employee': [638, 977], 'Group.': [642, 981], 'author': [644, 983], 'has': [645, 984], 'other': [647, 986], 'relevant': [648, 855, 987], 'affiliations': [649, 988], 'financial': [651, 660, 664, 990, 999, 1003], 'involvement': [652, 991], 'any': [654, 993], 'organization': [655, 994], 'entity': [657, 996], 'interest': [661, 1000], 'conflict': [665, 1004], 'subject': [668, 1007], 'matter': [669, 1008], 'materials': [671, 1010], 'discussed': [672, 1011], 'manuscript': [675, 1014], 'apart': [676, 1015], 'those': [678, 1017], 'disclosed.No': [679, 1018], 'writing': [680, 1019], 'assistance': [681, 1020], 'was': [682, 1021], 'utilized': [683, 1022], 'production': [686, 1025], 'manuscript.References1': [689], 'ML.': [691, 808], 'Neurodegenerative': [692, 918], 'discovery:': [694], 'building': [695], 'past,': [698], 'looking': [699], 'future.': [702], 'Med.': [704, 742, 771, 795, 822, 858, 883], 'Chem.': [705, 743, 772, 796, 823, 859, 884], '9(8),': [706], '(2017).Crossref,': [707], 'Medline,': [708], 'Google': [709, 746, 775, 799, 826, 862, 887], 'Scholar2': [710], 'World': [711], 'Health': [712], 'Organization.': [713], 'Dementia': [714], 'fact': [715], 'sheet.': [716], 'www.who.int/mediacentre/factsheets/fs362/en/.Google': [717], 'Scholar3': [718], 'E,': [720, 802, 835], 'Bartolini': [721], 'M,': [722], 'Abu': [723], 'IF': [724], 'Multitarget': [727, 915], 'disease:': [733], 'amyloid-beta': [739], 'aggregation.': [740], '9(10),': [744, 773, 797, 824, 860, 885], '(2017).Link,': [745, 774, 798, 825, 861, 886], 'Scholar4': [747], 'Pérez-Areales': [748], 'FJ,': [749], 'Betari': [750], 'N,': [751], 'Viayna': [752], 'A': [753], 'Design,': [756], 'synthesis,': [757], 'profiling': [761], 'generation': [765], 'anti-Alzheimer': [767], 'hybrids.': [769], 'Scholar5': [776], 'S,': [778], 'Giglio': [779], 'J,': [780, 831], 'Reyes': [781], 'AL': [782], '3-(Benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro-1H-indazole:': [785], 'PET': [787], 'measure': [790], 'brain.': [793], 'Scholar6': [800], 'Uliassi': [801], 'Gandini': [803], 'A,': [804, 867], 'Perone': [805], 'RC,': [806], 'Neuroregeneration': [809], 'vs': [810], 'neurodegeneration:': [811], 'towards': [812], 'paradigm': [814], 'shift': [815], 'discovery.': [820], 'Scholar7': [827], 'Babkova': [828], 'K,': [829], 'Korabecny': [830], 'Soukup': [832], 'O,': [833], 'Nepovimova': [834], 'D,': [837], 'Kuca': [838], 'K.': [839], 'Prolyl': [840], 'its': [843], 'organism:': [847], 'attention': [848], 'most': [851], 'clinically': [854], 'inhibitors.': [856], 'Scholar8': [863], 'SK,': [865], 'Dutta': [866], 'Modi': [868], 'G.': [869], 'Alpha-synuclein': [870], 'modulation:': [872], 'emerging': [874], 'treatment': [878], 'ScholarFiguresReferencesRelatedDetailsCited': [888], 'ByQSAR': [889], 'modelling:': [890], 'therapeutic': [892], 'patent': [893], '2010-present23': [895], 'May': [896], '2018': [897, 921], '|': [898], 'Expert': [899], 'Opinion': [900], 'Therapeutic': [902], 'Patents,': [903], 'Vol.': [904, 922], '28,': [905], '6Advanced': [907], 'Chemometric': [908], 'Modeling': [909], 'Approaches': [910], 'Design': [913], 'Drugs': [916], 'Against': [917], 'Diseases19': [919], 'Follow': [926], 'us': [927], 'social': [929], 'media': [930], 'latest': [933], 'updates': [934], 'Metrics': [935], 'History': [936], 'online': [938], '2017': [941, 946], 'print': [944], 'Information©': [947], 'LtdKeywordsα-synucleinantiaggregating': [950], 'inhibitorsAcknowledgementsSpecial': [954], 'manuscript.PDF': [1028], 'download': [1029]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2682941430', 'counts_by_year': [{'year': 2018, 'cited_by_count': 2}], 'updated_date': '2024-12-10T08:25:16.412944', 'created_date': '2017-06-30'}